The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global newborn screening market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Newborn screening is a public healthcare initiative focusing on infant screening, parental education, appropriate follow-up, diagnostic testing, disease management, and continued evaluation. It targets diseases that can cause significant morbidity, mortality, and intellectual disability (ID). Some of these diseases included in the newborn screening tests are galactosemia, phenylketonuria (PKU), homocystinuria, hearing loss, sickle cell disease (SCD), biotinidase deficiency, maple syrup urine, congenital adrenal hyperplasia, and medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Nowadays, public healthcare organizations across the globe are adopting new testing techniques, such as tandem mass spectrometry (MS/MS), to detect disorders associated with protein and fatty acid metabolism using blood samples.
The rising prevalence of congenital conditions among infants, along with increasing concerns among parents about the health of children, represents one of the significant factors influencing the market. Newborn screening relies on a specific set of laboratory evaluations and point-of-care examinations for early detection, diagnosis, and intervention of disorders. These disorders are genetic, metabolic, blood, or hormone-related, which are not immediately apparent after delivery and require practical intervention. This, coupled with the rising awareness about early diagnosis and improving diagnostic modalities, is propelling the growth of the market. Moreover, with the development of robust immunoassays and molecular diagnostics, disorders like primary hypothyroidism, cystic fibrosis (CF), and congenital toxoplasmosis are being targeted in several newborn screening tests. Apart from this, governing agencies of numerous countries are planning to mandate newborn screening programs due to increasing child morbidity and mortality, which is also contributing to market growth. Furthermore, the leading players are engaged in building strategic partnerships to ensure product sustainability, which is anticipated to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global newborn screening market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product, technology and test type.
Breakup by Product:
Breakup by Technology:
Breakup by Test Type:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Baebies Inc., Bio-RAD Laboratories Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, Masimo Corporation, Medtronic plc, Natus Medical Incorporated, Perkinelmer Inc., RECIPE Chemicals + Instruments GmbH, Thermo Fisher Scientific Inc., Trivitron Healthcare and Waters Corporation.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Technology, Test Type, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Baebies Inc., Bio-RAD Laboratories Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, Masimo Corporation, Medtronic plc, Natus Medical Incorporated, Perkinelmer Inc., RECIPE Chemicals + Instruments GmbH, Thermo Fisher Scientific Inc., Trivitron Healthcare and Waters Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at